Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocular Therapeut
(NQ:
OCUL
)
11.33
+0.24 (+2.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocular Therapeut
< Previous
1
2
3
4
5
6
7
Next >
Nike, Lululemon, Dick's Sporting Goods And Other Big Losers From Friday
October 03, 2022
U.S. stocks closed lower with the Dow Jones dropping 500 points on Friday. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Recap: Ocular Therapeutix Q2 Earnings
August 08, 2022
Ocular Therapeutix (NASDAQ:OCUL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 27, 2022
Gainers
Via
Benzinga
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
September 27, 2022
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
September 30, 2022
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Via
Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
September 28, 2022
Gainers
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
September 27, 2022
Gainers
Via
Benzinga
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
September 27, 2022
Via
Benzinga
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
September 27, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
September 22, 2022
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...
Via
Benzinga
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
July 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
June 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
June 01, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
May 26, 2022
On Thursday, 94 companies set new 52-week lows.
Via
Benzinga
Expert Ratings for Ocular Therapeutix
May 10, 2022
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 09, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
May 03, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
April 29, 2022
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Via
Benzinga
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
April 26, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.